PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2005 March; 6(1): E100–E107.
Published online 2005 September 20. doi:  10.1208/pt060116
PMCID: PMC2750417

Eudragit S100 entrapped insulin microspheres for oral delivery

Abstract

The purpose of this research was to investigate whether Eudragit S100 microspheres have the potential to serve as an oral carrier for peptide drugs like insulin. Microspheres were prepared using water-in oil-in water emulsion solvent evaporation technique with polysorbate 20 as a dispersing agent in the internal aqueous phase and polyvinyl alcohol (PVA)/polyvinyl pyrrolidone as a stabilizer in the external aqueous phase. The use of smaller internal aqueous-phase volume (50 μL) and external aqueous-phase volume (25 mL) containing PVA in the manufacturing process resulted in maximum encapsulation efficiency (81.8%±0.9%). PVA-stabilized microspheres having maximum drug encapsulation released 2.5% insulin at pH 1.0 in 2 hours. In phosphate buffer (pH 7.4), microspheres showed an initial burst release of 22% in 1 hour with an additional 28% release in the next 5 hours. The smaller the volumes of internal and external aqueous phase, the lower the initial burst release. The release of drug from microspheres followed Higuchi kinetics. Scanning electron microscopy of PVA-stabilized microspheres demonstrated spherical particles with smooth surface, and laser diffractometry revealed a mena particle size of 32.51±20 μm. Oral administration of PVA stabilized microspheres in normal albino rabbits (equivalent to 6.6 IU insulin/kg of animal weight) demonstrated a 24% reduction in blood glucose level, with maximum plasma glucose reduction of 76±3.0% in 2 hours and effect continuing up to 6 hours. The area under the percentage glucose reduction-time curve was 93.75%. Thus, our results indicate that Eudragit S100 microspheres on oral administration can protect insulin from proteolytic degradation in the gastrointestinal tract and produce hypoglycemic effect.

Keywords: insulin, oral, Eudragit S100, microspheres, hypoglycaemic

Full Text

The Full Text of this article is available as a PDF (1.1M).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release. 2003;90:261–280. doi: 10.1016/S0168-3659(03)00194-9. [PubMed] [Cross Ref]
2. Lee VC, Yalkowsky SH. Ocular devices for the controlled systemic delivery of insulin: in vitro and in vivo dissolution. Int J Pharm. 1999;181:71–77. doi: 10.1016/S0378-5173(98)00418-9. [PubMed] [Cross Ref]
3. Pillion DJ, Atchison JA, Stott J, McCracken D, Gargiulo C. Meezan E. Efficacy of insulin eye drops. J Ocul Pharmacol. 1994;10:461–470. doi: 10.1089/jop.1994.10.461. [PubMed] [Cross Ref]
4. Mitra R, Pezron I, Chu WA, Mitra AK. Lipid emulsions as vehicles for enhanced nasal delivery of insulin. Int J Pharm. 2002;205:127–134. doi: 10.1016/S0378-5173(00)00506-8. [PubMed] [Cross Ref]
5. Morishita M, Barichello JM, Takayama K, Chiba Y, Tokiwa S, Nagai T. Pluronic F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin. Int J Pharm. 2001;212:289–293. doi: 10.1016/S0378-5173(00)00615-3. [PubMed] [Cross Ref]
6. Yang TZ, Wang XT, Yan XY, Zhang Q. Phospholipid deformable vesicles for buccal delivery of insulin. Chem Pharm Bull. 2002;50:749–753. doi: 10.1248/cpb.50.749. [PubMed] [Cross Ref]
7. Hosny E, el-Ahmady O, el-Shattawy H, et al. Effect of sodium salicylate on insulin rectal absorption in humans. Arzneimittelforschung. 1994;44:611–613. [PubMed]
8. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release. 1999;62:279–287. doi: 10.1016/S0168-3659(99)00048-6. [PubMed] [Cross Ref]
9. Steiner S, Pfutzner A, Wilson BR, Harzer O, Heinemann L, Rane K. Technosphere/Insulin—proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes. 2002;110:17–21. doi: 10.1055/s-2002-19989. [PubMed] [Cross Ref]
10. Hosny EA, Al-Shora HI, Elmazar MA. Oral delivery of insulin from enteric coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. Int J Pharm. 2002;237:71–76. doi: 10.1016/S0378-5173(02)00024-8. [PubMed] [Cross Ref]
11. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J Control Release. 2000;65:261–269. doi: 10.1016/S0168-3659(99)00247-3. [PubMed] [Cross Ref]
12. Damge C, Vranchx H, Balschmidt P, Couvreur P. Poly (alkyl cyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci. 1997;86:1403–1409. doi: 10.1021/js970124i. [PubMed] [Cross Ref]
13. Kimura T, Sato K, Sugimoto K, et al. Oral administration of insulin as poly(vinyl alcohol)-gel spheres in diabetic rats. Biol Pharm Bull. 1996;19:897–900. [PubMed]
14. Mesiha M, Sidhom M. Increased oral absorption enhancement of insulin by medium viscosity hydroxypropyl cellulose. Int J Pharm. 1995;114:137–140. doi: 10.1016/0378-5173(94)00229-X. [Cross Ref]
15. Scott-Moncrieff JC, Shao Z, Mitra AK. Enhancement of intestinal insulin absorption by bile salt-fatty acid mixed micelles in dogs. J Pharm Sci. 1994;83:1465–1469. doi: 10.1002/jps.2600831020. [PubMed] [Cross Ref]
16. Qi R, Ping QN. Gastrointestinal absorption enhancement of insulin by administration of enteric microspheres and SNAC to rats. J Microencapsul. 2004;21:37–45. doi: 10.1080/02652040410001653786. [PubMed] [Cross Ref]
17. Nishihata T, Higuchi T, Kamada A. Salicylate promoted permeation of cefoxitin, insulin and phenylalanine across red cell membrane: Possible mechanism. Life Sci. 1984;34:437–445. doi: 10.1016/0024-3205(84)90498-3. [PubMed] [Cross Ref]
18. Kajii T, Hori T, Hayashi M, Awazu S. Effect of salicylic acid on the permeability of plasma membrane of small intestine of the rat: Fluorescence spectroscopic approval to elucidate the mechanism of promoted drug absorption. J Pharm Sci. 1986;75:475–478. doi: 10.1002/jps.2600750511. [PubMed] [Cross Ref]
19. Susuka T, Tata N, Sakai K, Nishihata T. The effect of salicylate concentration on the uptake of salicylate and cefmetazole into rat isolated small intestine epithelial cells. J Pharm Pharmacol. 1988;40:469–472. [PubMed]
20. Insel PA. Analgesic, antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's—The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996.
21. Rosa GD, Iommelli R, Rotonda MIL, Miro A, Quaglia F. Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres. J Control Release. 2000;69:283–295. doi: 10.1016/S0168-3659(00)00315-1. [PubMed] [Cross Ref]
22. Lee JH, Park TG, Lee YB, Shin SC, Choi HK. Effect of adding non-volatile oil as a core material for the floating microspheres prepared by emulsion solvent diffusion method. J Microencapsul. 2001;18:65–75. doi: 10.1080/026520401750038610. [PubMed] [Cross Ref]
23. Paul W, Nesamony J, Sharma CP. Delivery of insulin from hydroxyapatite ceramic microspheres: Preliminary in-vivo studies. J Biomed Mater Res. 2002;61:660–662. doi: 10.1002/jbm.10213. [PubMed] [Cross Ref]
24. Uchida T, Nagareya N, Sakakibara S, et al. Preparation and characterization of polylactic acid microspheres containing bovine insulin by w/o/w emulsion solvent evaporation method. Chem Pharm Bull. 1997;45:1539–1543. [PubMed]
25. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982. pp. 189–189.
26. Shargel L, Yu A. Applied Biopharmaceutics & Pharmacokinetics. 4th ed. London, United Kingdom: Prentice-Hall International, Inc; 1999. pp. 173–173.
27. Coombes AGA, Yeh MK, Lavelle EC, Davis SS. The control of protein release from poly (DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in-oil-in-water method. J Control Release. 1998;52:311–320. doi: 10.1016/S0168-3659(98)00006-6. [PubMed] [Cross Ref]
28. Sajeesh S, Sharma CP. Polymethacrylic acid-alginate semi-IPN microparticles for oral delivery of insulin: a preliminary in vestigation. J Biomater Appl. 2004;19:35–45. doi: 10.1177/0885328204042992. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists